Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network

17 Oct 2024

Abstract excerpt

ABSTRACT: We analyzed access barriers to anti-CD19+ chimeric antigen receptor T cells (CARTs) for non-Hodgkin lymphoma (NHL) within a community-based transplant and cell therapy network registry. A total of 357 intended recipients for approved anti-CD19+ CARTs were identified between 2018 to 2022. The median age at referral was 61 years; referral years were 2018 (4%), 2019 (14%), 2020 (18%), 2021 (26%), and 2022...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39418599
DOI: 10.1182/bloodadvances.2024014171

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 12 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy networkPMID 39418599Read ↗

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphomaSemantic proximity Read ↗

The Dutch CAR-T Tumorboard Experience: Population-Based Real-World Data on Patients with Relapsed or Refractory Large B-Cell Lymphoma Referred for CD19-Directed CAR T-Cell Therapy in The NetherlandsSemantic proximity Read ↗

Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.Semantic proximity Read ↗

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experienceSemantic proximity Read ↗

Remote monitoring of CAR T-cell treated patients by a specialized nurse to detect and manage late complications: report of the CARAMA programSemantic proximity Read ↗

Outcomes with bridging radiation therapy prior to chimeric antigen receptor T-cell therapy in patients with aggressive large B-cell lymphomasSemantic proximity Read ↗

Cancer Immunotherapy Implementation in Crisis-Affected MENA Settings (Lebanon, Sudan, and Iraq): A Pilot Descriptive-Analytical Cross-Sectional Study of Barriers, Clinical Readiness, and Policy PrioritiesSemantic proximity Read ↗

Real-world characteristics of T-cell apheresis and clinical response to tisagenlecleucel in B-cell lymphomaSemantic proximity Read ↗

Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia.Semantic proximity Read ↗

Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada.Semantic proximity Read ↗

TREATMENT OUTCOME AND PREDICTORS OF PEDIATRIC NON-HODGKIN LYMPHOMA IN ETHIOPIASemantic proximity Read ↗

Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 daysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.